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INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is a avoidable 
and treatable common disease characterized by progressive and 
permanent airflow limitation associated with increased chronic 
inflammatory response of the lungs and airways against injurious gases 
and particles. One of the characteristic features of COPD is acute 
exacerbations, which usually are associated with increased inflammation 
due to infections and/or environmental factors. It is possible that bacterial 
colonization itself, or recurring and intermittent exacerbation caused by 
the colonization, may contribute to chronic airway inflammation and the 
progression of COPD. Inflammation is a complex set of relations among 
various immune-related cells, including neutrophils and lymphocytes, 
which can lead to persistent tissue damage if targeted destruction and 
assist repair are not properly phased. 
Leucocyte count and its subtypes are well-known markers of 
inflammation. Since the physiological response of the leucocytes in 
circulation against stress precipitates an increase in neutrophil count and 
decrease in the lymphocyte count, the ratio of these two sub-groups to 
one another is engaged in the intensive care practice. In various recent 
studies, neutrophil-to-lymphocyte ratio (NLR) has been evaluated for its 
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probable role in the inflammation periods of chronic diseases such as 
pancreatitis, acute coronary syndrome etc. 
It has been established in previous studies that various 
inflammatory markers like C-reactive protein (CRP), fibrinogen and 
leucocyte count increase in stable patients of COPD as well as in 
exacerbation and that this increase is associated with the negative results 
of the disease. Unlike other inflammatory biomarkers e.g., ESR and CRP, 
the Neutrophil–lymphocyte ratio (NLR) is derived from routine complete 
blood count (CBC) tests. It does not need a special request. It is a rapid, 
easy and cost-effective method. 
The current study is undertaken to analyse the Neutrophil to 
lymphocyte ratio(NLR) in COPD exacerbation and stable COPD patients. 
Also to check whether the NLR could reflect the disease severity in such 
patients as compared with BODE score in COPD. 
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AIMS AND OBJECTIVES 
 
 To assess whether Neutrophil-to-Lymphocyte ratio can be used to 
assess the severity of disease by comparing it with BODE score 
in COPD 
 To assess whether the Neutrophil Lymphocyte ratio is higher in 
COPD exacerbation compared to patients with stable COPD  
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REVIEW OF LITERATURE 
 
NEUTROPHILS 
Neutrophils play imperative part in defence of humans and 
sometimes it can injure our own tissue. In the resting host,the production 
and removal of neutrophils are balanced. But at times of stress, 
chemotactic agents are generated that result in neutrophil recruitment and 
activation of defense mechanisms. 
SUBCELLULAR STRUCTURE 
 Many types of machinery are within neutrophill when seen by 
electron microscopy. They are 
1. Granules 
2. cell membrane 
3. Cellular Matrix 
4. Layers of Lipid 
5. lipid bodies 
6. Cytoplasm 
7. Multilobed nucleus 
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Neutrophilic Granules 
1.  Primary (azurophilic) granules 
 Antimicrobial enzymes like myeloperoxidase are found in 
neutrophil, which catalyses the production of hypochlorite through 
oxidative burst. Other contents include lysozyme, bactericidal 
permeability increasing protein that alters cell permeability, azurocidin, 
proteinase 3, esterase and others. 
2.  Secondary (specific) granules 
 They are chiefly released into extracellular space and include 
apolactoferrin, Vit B12-binding protein, plasminogen activator and 
collagenase. The lack of specific granules predisposes to skin and 
respiratory infections. 
3. Tertiary (Gelatinase) granules 
 It contains gelatinase, Acetyltansferase, Lysozyme, NRAMP1 and 
ficolin-1, which are upregulated to the cell surface with stimulation. 
4.    Secretory Vesicles 
 Secretory vesicles contain preformed enzymes which are secreted 
readily stimulation 
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PLASMA MEMBRANE 
 It is constituted by ionic channels, ligands, lipid layer for 
communication in and out of neutrophil. 
CYTOSKELETAL MATRIX 
 Its apparatus include actin, actin binding protein, gelsolin, myosin, 
tubulin and tropomyosin that help in phagocytosis and exocytosis. 
NEUTROPHIL LIPIDS  
 Lipids account for 5% of neutrophils by weight, of which 35% is 
phospholipid. Plasma membrane and secretory vesicles contain 
approximately half of the cellular phospholipid. The presence of 
arachidonic acid in phospholipids is an important precursor of lipoxins, 
leukotrienes and prostaglandins.. Non phospholipid neutrophil lipid is 
chiefly constituted by cholesterol and triglycerides. Glycolipids constitute 
the remaining 
CYTOSOL 
 Around 50% of cytosolic protein appears to be migration inhibitory 
factor related proteins (MRPs). MRP 7 and MRP 13 are members of S 
100 family of calcium binding proteins. MRP 13 can result in 
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macrophage activation. Annexin 1 is the mediator of anti-inflammatory 
effects of glucocorticoids. 
NUCLEUS 
 Mature neutrophils can produce RNA and protein. This is of 
particular significance when they migrate to sites of inflammation. 
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STAGES OF DEVELOPMENT OF NEUTROPHIL. 
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PHYSIOLOGIC VARIATION IN NEUTROPHILS 
 By the age of 4-8 years, the blood differential count approaches 
that of the adult. Racial variations were reported in black Africans with 
reduced neutrophil and monocyte and elevated eosinophil counts.. Under 
conditions of complete physical and mental relaxation, a basal level of 
5.0- 7.0 x 109 cells/l is usual.Ordinary activity is associated with a 
moderate increase and a fairly higher level is common in afternoon. 
Heat and strong solar radiation are said to cause leukocytosis. 
Artificially induced heat, sunlight and UV light have been reported to 
cause lymphocytosis. Acute anoxia, both anoxic and anemic, causes 
neutrophilic leukocytosis. 
 Marked leukocytosis occurs regularly with laborious exercise. The 
increment of cells usually consist of segmented neutrophils, but 
lymphocytosis may be prominent as well. Such leukocytosis recedes to 
normal in less than an hour. The magnitude of leukocytosis related with 
exercise appears to depend primarily on the amount of the activity. 
Similarly, convulsive seizures are associated with an increase in 
leukocyte count. 
 Epinephrine injection produces leukocytosis, the nature and 
duration of which appear to vary with the mode of administration.  
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 During attacks of paroxysmal tachycardia, leukocytosis with cell 
counts of 13.0- 22.0 x 109 has been reported. Pain, nausea and anxiety 
may cause leukocytosis. The Paucity of band forms and metamyelocytes 
indicates that the neutrophilia results from redistribution of cells between 
marginal and circulating pools. 
 Many of the physiologic variations in leukocytes that have been 
described can be explained as manifestations of stimulation of adrenal 
cortex 
REGULATION OF NEUTROPHIL PRODUCTION 
 The nature of control mechanisms is intricate but several control 
points exist: 
• Recruitment of pluripotent stem cell and making them commitment 
into committed stem cells, 
• Stimulation of stem cell and myeloid proliferative cell growth and 
• Selective release of cells from marrow 
 Several factors that promote neutrophil release from the marrow 
has been identified including 
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• C5a, 
• TNF alpha, 
• TNF beta, 
• IL-8 etc 
SEQUENCE OF NEUTROPHIL ENDOTHELIAL CELL 
ADHESION 
Tethering    Rolling           Adhesion   Transmigration 
A gorgeous model for neutrophil-endothelial cell adhesion was 
proposed by Springer. According to it, Selectins are responsible for the 
initial rolling of neutrophils along the endothelial cell. Stimulation of 
neutrophils can result in a rapid increase in L-selectin affinity for its 
ligand resulting in tethering of a flowing cell and rolling within a 
millisecond. 
 Interaction of chemoattractant molecules on the endothelial surface 
with ligand receptors of neutrophil result in signal transmission and 
activation of integrin molecules. These integrins can bind their ligands on 
the endothelial surface, resulting in a marked increase in adhesion to 
endothelial cell and cessation of rolling. After this, further 
chemoattractant molecules are sensed by cells and migrate into the tissues 
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where neutrophils produce compounds that attract other inflammatory 
cells. 
SELECTINS 
 Three major selectins have been identified. L-selectin is expressed 
on the neutrophil surface and its main ligand is a glycoprotein known as 
Gly-CAM-1. Endothelial cells exhibit both E-selectin and P - selectin, 
both of which recognize Lewisx-related sialylated carbohydrates. 
Expression of E-selectin on the vessel surface can be induced with 
stimuli such as IL-1 and TNF but requires protein synthesis. Thus 
stimulation of endothelial cells with appropriate stimulus like thrombin or 
histamine, can effect in a rapid mobilisation of P-selectin to the 
endothelial cell surface. 
INTEGRINS 
 They are heterodimers of alpha and beta subunits which are 
connected by non-covalent bond. The important integrins of neutrophil 
are the Beta-2 integrins. ICAM 1 expressed on the vascular endothelial 
cell surface is its ligand. Other Ig superfamily members are also involved, 
including PECAM-1, ICAM-3 etc 
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CHEMOTAXIS 
 Chemotaxis starts with the formation of protrusion known as 
pseudopodium or lamellopodium at the front of the cell. When the cell 
started to move, the pseudopodium ruffles rapidly and portion of the 
pseudopodium attaches to the underlying surface and the contents of the 
cell move forward into the pseudopodium making the pseudopodium less 
prominent. This cycle is repeated. In leukocytes, the contraction 
waveappears to derive in the superficial layer called cortex. Gelsolin 
plays an important role in neutrophil chemotaxis. 
SECRETORY FUNCTIONS OF NEUTROPHIL 
A number of substances are released by WBC in vitro. Specific 
granule release occurs before the primary granule release. Both tertiary 
granules and secretory vesicles are released even more rapidly. Two 
modes of enzyme release are, (a) release in to phagocytic vacuoules and 
(b) true secretion. Lysozyme is present in primary, secondary and tertiary 
granules and also in monocytes, serum, tear and other secretions. 
Stimulated neutrophils can produce and discharge a variety of 
inflammatory mediators. Neutrophils stimulated with lipopolysaccharides 
synthesize IL-1, TNF- alpha and IL-1 receptor antagonist, whereas GM-
CSF stimulates the production of TNF- alpha and IL-6. On entering the 
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tissue, neutrophil begin to synthesize cytokines, including the ones that 
attract other inflammatory cells. In general, diapedesis seems to induce an 
anti-apoptotic state while phagocytosis promotes apoptosis. 
INFLAMMASOMES 
IL-1beta is involved in many inflammatory responses. TLR 
binding to PAMPs result in transcription of Pro-IL-1beta, which is 
processed by a multimolecular complex termed inflammasome, which 
converts pro caspase 1 to its active form, which then cleaves Pro-IL-1 
beta to IL-1beta. Inflammasomes are present in neutrophils and 
macrophages. Other neutrophil proteases, including elastase, proteinase 3 
and cathepsin G can convert Pro IL-1beta to its active form. 
NEUTROPHIL EXTRACELLULAR TRAPS (NETs) 
Neutrophils can extrude DNA, histones and granule contents to 
form structures termed NETs. Microbes can be trapped in these NETs 
and be killed. 
LYMPHOCYTES 
Lymphocytes are heterogenous population of cells. They differ 
greatly regarding there origin, life span, preferred areas of settlement 
within lymphoid organs. Most lymphocytes are small(10 micrometer or 
less).Large lymphocytes named as large granular lymphocytes which 
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contain azurophilic granules in their cytoplasm are also found .Depending 
on their interaction with correct stromal cells and other growth 
stimulators, stem cells differentiate into T cells , B cells and other 
lineages. In thymic microenvironment Tcells develop and with marrow 
derived stromal cells they develop as B -lymphocytes or myeloid cells. 
Normal lymphopoiesis depends on Ikaros family of transcription factors. 
 Although most lymphocytes in normal lymphoid tissue look alike 
when studied under a microscope, these cells are distinctly divided into 
two major populations. One of the populations, the T lymphocytes, is 
responsible for forming the activated lymphocytes that provide cell-
mediated immunity, and the other population, the B lymphocytes, is 
responsible for forming antibodies that provide humoral immunity 
Both types of lymphocytes are initially from the embryo started as 
pluripotent hematopoietic stem cells that form common lymphoid 
progenitor cells as one of their most important offspring as they 
differentiate. 
Nearly all of the lymphocytes that are formed ultimately end up in 
the lymphoid tissue, where they are further differentiated or preprocessed 
in the following ways. 
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The lymphoid progenitor cells that are destined to eventually form 
activated T lymphocytes first migrate to and are preprocessed in the 
thymus gland, and thus they are called T lymphocytes to designate the 
role of the thymus. They are responsible for cell-mediated immunity. 
The other population of lymphocytes-the B lymphocytes that are 
destined to form antibodies-are preprocessed in the liver during mid-fetal 
life and in the bone marrow in late fetal life and after birth. This 
population of cells was first discovered in birds, which have a special 
preprocessing organ called the bursa of Fabricius. For this reason, these 
lymphocytes are called B lymphocytes to designate the role of the bursa, 
and they are responsible for humoral immunity 
When specific antigens come in contact with T and B lymphocytes 
in the lymphoid tissue, certain of the T lymphocytes become activated to 
form activated T cells, and certain of the B lymphocytes become 
activated to form antibodies. The activated T cells and antibodies in turn 
react highly specifically against the particular types of antigens that 
initiated their development. The mechanism of this specificity is the 
following. 
Millions of Specific Types of Lymphocytes Are stored in the 
Lymphoid Tissue .Millions of different types of preformed B 
lymphocytes and preformed T lymphocytes that are competent of forming 
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highly specific types of antibodies or T cells have been stored in the 
lymph tissue, as explained prior. Every preformed lymphocytes has the 
capacity to form only one type of antibody or one type of T cell with a 
single type of specificity. And only the corresponding type of antigen 
which it can bind with can activate it. After the specific lymphocyte is 
activated by its antigen, it multiplies wildly, forming large numbers of 
similar lymphocytes. 
 If it is a B lymphocyte, its progeny will eventually secrete the 
specific type of antibody that then circulates throughout the body. 
 If it is a T lymphocyte, its progeny are specific sensitized T cells 
that are released into the lymph and then carried to the blood and 
circulated through all the tissue fluids and back into the lymph, 
sometimes circulating around and around in this circuit for months 
or years. 
Neutrophils comprise 40-75% (1800-7700/l) and lymphocytes 20-50% 
(1000-4800/l) of the total leucocyte count 
LYMPHOCYTOSIS is said to occur when there is an increase in absolute 
counts of lymphocytes. It should not be applied to an increase in relative 
proportion of lymphocytes in the absence of an absolute increase in 
lymphocyte count. 
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Causes of Lymphocytosis 
1.  Pertusis 
2. Typhoid 
3. Tuberculosis 
4. Secondary Syphilis 
5. Tropical Splenomegaly Syndrome 
6. Epstein Barr Virus Infection, 
7. Cytomegalovirus 
8. Leukemias are some causes of lymphocytosis. 
 
LYMPHOPENIA is said to occur when the absolute lymphocyte count 
is below the conventionally employed lower limit of normal 1.5 *109. 
Lymphopenia is common in leucopenic prodromal phase of many 
viral infections, pancytopenia due to any cause, steroid intake and many 
more. 
Inflammation is stirred by chemical mediators that are produced in 
host cells in response to deleterious injury or stimuli. When cardiac tissue 
is injured, the presence of damage is sensed by resident cells mainly 
macrophages, neutrophils & lymphocyte and also dendritic cells, mast 
cells, and other cell types. These cells secrete molecules (cytokines and 
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other mediators) that induce and regulate the subsequent inflammatory 
response. 
Inflammatory mediators are also produced from plasma proteins 
that react with the injured tissues. Some of these mediators stimulate the 
efflux of plasma and the enrolment of circulating leukocytes to the 
inflammatory site where the offending tissue is located. 
 All these recruited leucocytes are activated and they try to remove 
the offending tissue by phagocytosis. 
An unfortunate side effect of the activation of leukocytes is that it 
may cause injury to normal host cells also. Acute inflammatory process 
occurring as a result of an insult to a tissue or organ has two major 
components: 
Vascular changes 
Changes in vessel caliber causes an augmented blood flow 
(vasodilation) and alterations in the vessel wall that allows plasma 
proteins like albumin to leave the intravascular circulation (increased 
vascular permeability). In addition, endothelial cells are activated, 
resulting in increased adhesion of neutrophils, lymphocytes along with 
macrophages and relocation of these agents through the vessel wall. 
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Cellular events 
 Migration of the leukocytes from the circulation and gathering in 
the focus of injury (cellular recruitment), followed by activation of the 
leukocytes (neutrophils, lymphocytes, macrophages) enabling them to do 
the repair or to remove the necrotic debri. The principal leukocytes in 
acute inflammation are neutrophils (polymorphonuclear leukocytes). 
Multiple mechanisms may lead to transient or permanent increase in 
vascular permeability in acute inflammatory reactions: 
1. Vascular Endothelial cell contraction that forms intercellular gaps 
in post capillary venules is the most common cause of increased 
vascular permeability. 
2. Endothelial injury results in vascular leakage by causing 
endothelial cell necrosis and detachment 
3. Increased transcytosis of proteins by way of an intracellular 
vesicular pathway augments venular permeability after exposure to 
particular mediators like vascular endothelial growth factor 
(VEGF) 
4. Leakage from new blood vessels. 
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Leukocyte Recruitment 
Leukocytes usually flow rapidly in the blood, and in inflammation, 
they have to be stopped and brought to the the site of tissue damage, 
which are usually outside the vessels. The sequence of events in the 
recruitment of leukocytes from the vascular lumen to the extravascular 
space consists of 
a) Margination and rolling along the vessel wall. 
b) Firm adhesion to the endothelium. 
c) Transmigration between endothelial cells 
d) Migration in interstitial tissues toward a chemotactic stimulus. 
 Rolling, adhesion, and transmigration are mediated by the 
interactions of adhesion molecules on leukocytes and endothelial 
surfaces. 
 Chemical mediators which act as chemoattractants and certain 
cytokines can affect these processes by modulating the surface expression 
and binding properties of leucocytes. 
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Mechanisms of leukocyte migration through blood vessels 
The leukocytes (neutrophils shown here) first roll, then become 
activated and hold on to endothelium, and then transmigrate across the 
endothelium, pierce the basement membrane, and migrate toward 
chemoattractants emanating from the source of injury. 
Different molecules play predominant roles in different steps of 
this process: selectins in rolling. chemokines (usually displayed bound to 
proteoglycans) in activating the neutrophils to increase avidity of 
integrins. The various chemo attractants and binding receptors are 
 Integrins in firm adhesion and 
 CD31 (PECAM-1) in transmigration. 
 ICAM-1, intercellular adhesion molecule-1; 
 IL-1, interleukin-1; 
 PECAM-1, platelet endothelial cell adhesion molecule-1; 
 TNF, tumor necrosis factor. 
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In most forms of acute inflammation, neutrophils dominate in the 
inflammatory infiltrate during the first 6 to 24 hours and are replaced by 
monocytes in 24 to 48 hours .Several factors account for this early 
abundance of neutrophils: These cells are the most numerous leukocytes 
in the blood, they respond more rapidly to chemokines, and they may 
attach more firmly to the adhesion molecules that are rapidly induced on 
endothelial cells. But are short-lived—they die by apoptosis and 
disappear within 24 to 48 hours—while monocytes survive longer. 
Because leukocytes are capable of secreting potentially harmful 
substances such as enzymes and reactive oxygen, they are important 
causes of injury to normal cells and tissues under several circumstances 
.For example, after a myocardial infarction as an effort to clear injured 
and dead tissues in an infarct, inflammation may extend and aggravate the 
injurious consequences of the ischemia, especially on reperfusion. 
Lymphocytes are mobilized in the setting of any specific immune 
stimulus (i.e., infections) as well as non–immune mediated inflammation 
(e.g., due to ischemic necrosis), and are the major drivers of 
inflammation in many chronic inflammatory diseases. 
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 By secreting cytokines, CD4+ T lymphocytes promote 
inflammation and alters the course of the inflammatory reaction. There 
are 3 types of CD4+ helper T cells. They secrete different types of 
cytokines and produce different types of inflammation: 
 
1. TH1 cells secrete the cytokine IFN-γ that alters inflammation by 
activating macrophages, thus stimulating classical complement 
pathway 
2. TH2 cells secrete IL-5, IL-13, and IL-4, which recruit and stimulate 
eosinophils, thus activating alternate complement pathway. 
3. TH17 cells secrete IL-17 and other cytokines that induce the 
secretion of chemokines responsible for recruiting neutrophils and 
monocytes into the reaction. 
4. Activated lymphocytes and macrophages stimulate each other, and 
both cell types release inflammatory mediators that affect other 
cells. 
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NEUTROPHIL-LYMPHOCYTE RATIO 
There has been a recent focus on differential WBC count in 
predicting cardiovascular risk of the many cell types used like neutrophil 
count, lymphocyte count, monocyte count, neutrophil lymphocyte ratio 
(NLR) is found to have predictive superiority. Elevated neutrophil level 
and decreased lymphocytes are independent predictors of poor outcome 
in COPD and various other cardiac conditions but NLR ratio is superior 
to either of these alone Reasons for its superiority include: 
1. Though physiological conditions like dehydration and exercise 
might alter the absolute number of individual cell types, the ratio 
remains less affected 
2. NLR is a ratio of two different complementary immune pathways. 
Neutrophils are involved in quicker response while lymphocytes 
are related to more adaptive long term response. 
Integrated reflection of two important and opposite immune pathways 
is more dependable than either alone. NLR is cheap, easily assesable and 
readily available marker that can help in risk stratification of patients 
with various diseases .Elevated NLR is associated with arterial stiffness 
& progression of atherosclerosis. An increased neutrophil count might 
reflect inflammation and lymphopenia is an indicator of physiologic 
stress due to increased levels of corticosteroids & lymphocyte apoptosis. 
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Neutrophils produce the enzyme myeloperoxidase that is involved in 
promoting phagocytic function of neutrophils, but high levels of this 
enzyme can cause excess production of free radicals which is responsible 
for tissue injury. 
Biomarkers are now being more and more used in diagnosing 
various conditions and also for determining short and long term 
prognosis. Role of biomarkers in our clinical practice is expected to grow 
tremendously in coming years. Inexpensive and readily available 
biomarkers like NLR will be of great use in assessing prognosis of 
patients admitted with various conditions like COPD 
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Chronic Obstructive Pulmonary Disease [COPD]  
 COPD has been defined as “a disease state characterised by airflow 
limitation that is not fully reversible.” COPD includes emphysema, 
anatomically defined by the destruction and enlargement of distal 
airspaces; chronic bronchitis, clinically defined by chronic cough and 
sputum; and small airways disease causing bronchiolar narrowing. 
RISK FACTORS 
1. Cigarette smoking is definitively the most important individual 
causative factor of COPD. However, only 20% of smokers go on to 
develop clinically significant disease. Pack years of smoking is the most 
highly significant predictor of FEV1. 
 
 
 
 
 
The above table depicts the effect of age on airflow obstruction in 
normal subjects and in susceptible cigarette smokers. Quitting the 
smoking habit will return the rate of decline to the normal trend. 
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The above chart depicts the mean FEV1 after bronchodilator 
administration in ex-smokers who maintained abstinence compared 
with smokers who continued to smoke. 
2. Airway hyperresponsiveness, one of the characteristic features of 
bronchial asthma, is seen in many patients with COPD. 
Overlap between asthma and COPD was the basis for the 
development of Dutch hypothesis which proposes that asthma, 
emphysema and chronic bronchitis are variations of the same 
disease, altered by genetics and environment to produce these 
phenotypes. 
The British hypothesis proposes that asthma is completely 
diverse from COPD-asthma being an allergic phenomenon and COPD 
the sequel of smoking related inflammation and damage. 
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A non-proportional Venn diagram telling the relation between 
asthma, emphysema and chronic bronchitis/ the broken line rectangle 
includes all patients with airflow obstruction. Patients in subsets 1 and 2 
have clinical or radiological features of chronic bronchitis or 
emphysema but do not have airflow obstruction and thus have a normal 
FEV1 and FEV1/FVC ratio. These patients are not classified as having 
COPD. Patients in subsets 6-8 have partially reversible airflow 
obstruction. Subsets 3-5 have no significant reversibility and patients in 
subset 8 have features of all three disorders. Those in subset 9 have 
completely reversible airflow obstruction and thus classified as asthma. 
Those in subset 10 have airflow obstruction due to specific causes like 
cystic fibrosis, bronchiectasis. Patients with COPD are those within the 
thick shaded band. 
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3. Ambient air pollution is a much less significant risk factor than 
cigarette smoking.  
4. Passive smoking exposure has been linked to decreased lung 
function, but relation with COPD remains unproven 
PATHOGENESIS OF COPD 
Both chronic bronchitis and emphysema produce airway narrowing 
but evidence of obstruction need not be present. Airway obstruction is 
always seen by the time the patient becomes dyspnoeic. Airflow 
limitation, which is the major physiological change in COPD, can result 
from both small airway obstruction and emphysema. 
PROTEASE- ANTIPROTEASE THEORY  
Cigarette smoke has a pro- oxidant effect, which makes 
neutrophils less deformable and causes neutrophil sequestration in the 
pulmonary capillaries. Activated neutrophils initially adhere to the 
endothelium and then migrate to the airspaces. The pro-oxidants from 
cigarette smoke or released by activated airspace neutrophils inactivate 
antiproteases, mainly elastase. Elastase enters the lung interstitium and 
destroys elastin, causing destruction and enlargement of distal airspaces. 
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INFLAMMATION AND EXTRACELLULAR MATRIX  
HYPOTHESIS 
Macrophages and epithelial cells are activated on exposure to 
oxidants in cigarette smoke and produce chemokines that attract 
inflammatory cells, for example matrix metalloproteinases, IL-8 and 
TNF which lead to neutrophil recruitment.CD8+T cells are also recruited 
and release interferon inducible protein-10 (IP-10) which simulate 
macrophage production of macrophage elastase- matrix 
metalloproteinase-12. 
Matrix metalloproteinases and serine proteinases (especially 
neutrophil elastase) work synergistically by degrading the other’s 
inhibitor and produce lung destruction. 
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TYPES OF EMPHYSEMA 
 
 
 
 
 
 
 
 
 
 
• Centriacinar- destruction of central acinus, commonly 
affect upper lobes, common in smokers 
• Panacinar- widespread destruction of acinus, commonly 
affect lower zones, common in antitrypsin deficiency 
• Paraseptal- affects the distal acinus, can cause spontaneous 
pneumothorax 
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The above picture demonstrates the multiple individual pathologies 
ultimately leading to small airway disease with reduction of FEV1. 
CELL DEATH AND INEFFECTIVE REPAIR 
Structural cell death caused by oxidants in cigarette smoke occurs 
through a number of mechanisms, including rt801 inhibition of 
mammalian target of rapamycin (mTOR), leading to cell death and 
proteolysis. Involvement of mTOR and other senescence indicators has 
funded recent theories that emphysema is a type of premature accelerated 
ageing of lung. Macrophage uptake of apoptotic cells is inhibited by 
cigarette smoke, which limits repair. 
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PATHOPHYSIOLOGY OF COPD 
Persistent reduction in forced expiratory flow rates is the most 
classical finding in COPD. 
AIRFLOW OBSTRUCTION 
Also known as airflow limitation, it is assessed by spirometry, by 
forced expiratory maneuvers after patient inhales to total lung capacity. 
Most essential measurements are the volume of air exhaled in the first 
second of the forced expiratory maneuver (FEV1) and the total volume of 
air exhaled during the complete spirometric maneuver [Forced Vital 
Capacity (FVC)]. Airflow obstruction of COPD is identified by a 
persistently reduced FEV1/FVC ratio. Unlike bronchial asthma, the 
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decreased FEV1 in COPD does not show improvements more than 15% 
in response to inhaled bronchodilators. 
The airflow in forced exhalation depends upon the balance 
between elastic recoil of the lungs which assists flow and the airway 
resistance inhibiting flow. In COPD, maximal expiratory flow decreases 
as the lung empties because the parenchyma gives progressively less 
recoil and the airflow resistance increases due to decrease in airway cross 
sectional area. 
HYPERINFLATION 
Pulmonary function tests also measure lung volumes. “Air 
trapping” (increased residual volume and increased ratio of residual 
volume to total lung capacity) and increasing hyperinflation (increased 
total lung capacity) occurs in COPD. Hyperinflation is an initial 
compensatory mechanism which helps in maintaining maximal 
expiratory airflow, as the increased lung volume increases the elastic 
recoil and the airways enlarge decreasing the airway resistance. 
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However, the flattening of diaphragm due to hyperinflation of 
lungs is not good for the COPD patient: 
1. As diaphragm and abdominal wall are now closely apposed, 
positive abdominal pressure in inspiration cannot be as effectively 
delivered to chest, which decreases rib cage movement and 
reduces inspiration. 
2. The muscle fibres of the flattened diaphragm are shorter than 
normal and hence, not able to produce normal inspiratory 
pressures. 
3. Flat diaphragm has more radius of curvature r, hence, increased 
tension t must be produced to maintain transpulmonary pressure p 
for tidal breathing-{LAPLACE LAW p=2t/r} 
4. Inspiratory muscles must overwork to overcome the resistance of 
the expanded thoracic cage. 
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Diagram depicting the mechanisms by which flat diaphragm 
eventually contributes to COPD mortality 
GAS EXCHANGE 
Partial pressure of oxygen in arterial blood (PaO2) remains normal 
until FEV1 decreases to less than 50% of predicted. Increased PaCO2 
occurs only when FEV1 decreases to less than 25% of predicted. 
Pulmonary hypertension causing cor pulmonale and right 
ventricular failure occurs when FEV1 decreases to less than 25% of 
predicted with chronic hypoxemia (PaO2 < 55mm Hg). 
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Mechanisms of development of Pulmonary Hypertension in COPD 
 Degeneration of the vascular bed in lungs 
 Alterations in blood gas tension 
 Alterations in lung mechanics 
 Elevated cardiac output 
 Alterations in blood volume 
 Increased velocity of blood 
 Changes in lung endothelium 
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DIAGNOSIS 
COPD must be thought of in patients with chronic complaints of 
cough, sputum production or dyspnea with history of smoking and 
exposure to risk factors. 
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SEVERITY SCORES FOR RESPIRATORY DISEASES 
 
 
 
 
 
 
A patient with a BODE score of 0-2 has a mortality rate of around 
10% at 52 months,whereas a patient with a BODE score of 7-10 has a 
mortality rate of around 80%  at 52 months. 
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MMRC Dyspnoea Scale 
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Spirometry 
 
 
 
 
 
 
 
 
 
A post bronchodilator FEV1/ FVC < 0.7 confirms airway 
obstruction that is not completely reversible.  
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GOLD CRITERIA FOR COPD 
 
IMAGING  
Chest X-ray may be normal or show emphysematous changes. It is 
very helpful in ruling out other differential diagnoses and in detecting 
complications of COPD, including life threatening ones like 
pneumothorax. Patients with chronic bronchitis may have thick bronchial 
walls which appear as tubular or tram track shadows with increased 
vascular markings. 
Chest X-ray in symptomatic emphysematous patients reveals dark 
hyperlucent lung fields with decreased vascular markings, characteristic 
bullae, flattened and pushed-down diaphragm and tube-like heart. 
GOLD Stage SEVERITY SPIROMETRY 
   
I Mild FEV1/FVC<0.7 and FEV1 
  >80% predicted 
   
II Moderate FEV1/FVC<0.7 and FEV1 
  >50% but <80% predicted 
   
III Severe FEV1/FVC<0.7 and FEV1 
  >30% but <50% predicted 
   
IV Very Severe FEV1/FVC<0.7 and FEV1 
  <30% predicted 
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HRCT can readily detect emphysema but is not used routinely for the 
purpose of diagnosis. Contrast-enhanced computed tomography (CECT) 
chest may show a dilated pulmonary artery, indicating pulmonary 
hypertension. 
ACUTE EXACERBATION 
An exacerbation is defined as an episode of increased cough, 
dyspnea and altered volume and character of sputum, with or without 
other signs of disease. The frequency of exacerbations greatly affects 
quality of life of COPD patients, especially those with GOLD stage III 
or IV, who experience one to four exacerbations in a year. 
Chances of exacerbation in future are increased by a previous 
history of exacerbation and an increased ratio of pulmonary artery 
diameter to aorta diameter on Chest CT. 
Bacterial infection causes more than half of exacerbations, 
with viral infections being involved in 30% and remaining 20 % 
cases having no obvious precipitating cause. 
Prevention of exacerbations is achieved to a great degree of 
success with inhaled steroids, anticholinergics and long acting beta 
agonists. 
Treatment is by inhaled beta agonists, along with anticholinergic 
agent, antibiotics, oral glucocorticoids and supplemental O2. 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
TITLE 
NEUTROPHIL LYMPHOCYTE RATIO AS A MARKER OF 
DISEASE SEVERITY AND EXACERBATION IN COPD 
STUDY DESIGN 
   Analytical Cross-sectional study 
STUDY PERIOD 
SEPTEMBER 2016 to SEPTEMBER 2017(1 year) 
SELECTION OF STUDY SUBJECTS 
The study is to be conducted among 80 patients which includes 30 
patients who attend the emergency department of Gov.Rajaji Hospital, 
Madurai in a state of COPD Acute exacerbation and 50 Stable COPD 
patients who attend the OPD for followup.  
Criteria for COPD Exacerbation- any patient with a worsening of 
more than two respiratory symptoms (dyspnoea,sputum,cough or wheeze) 
for two or more consecutive days can be considered as exacerbation. 
Criteria for stable COPD-no symptoms of exacerbation and no use 
of systemic corticosteroids or antibiotics for the preceding 8 weeks. 
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INCLUSION CRITERIA 
All patients with a confirmed diagnosis of COPD diagnosed with 
pulmonary function test according to GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) criteria 
EXCLUSION CRITERIA: 
 Bronchial asthma, bronchiectasis, or bullous lung disease 
 Active tuberculosis or any history of pulmonary fibrosis 
 Any tumor, hepatitis, thyroid diseases, autoimmune diseases, or 
any other acute infections 
 Dementia 
 Receiving systemic corticosteroids, antibiotics, or 
immunosuppressive treatment 
 Not free from an Exacerbation for at least preceeding 8 weeks 
 Withdrawal of consent 
ANTICIPATED OUTCOME 
Neutrophil-to-lymphocyte ratio is expected to be elevated in COPD 
patients and is a marker of disease severity in stable COPD patients in 
comparison with BODE score. NLR value is expected to increase during 
acute exacerbation. 
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METHOD OF COLLECTION OF DATA 
Patients with acute exacerbation of COPD brought to the Medicine 
casualty and also stable COPD patients attending the Thoracic Medicine 
OPD of Gov.Rajaji Hospital, Madurai. 
Informed consent was taken 
A detailed history including duration of illness, smoking history, 
pack-years and any past medical history was taken. 
Degree of dyspnoea was assessed using Modified Medical 
Research Council (MMRC) dyspnoea scale 
Body mass index calculated. 
Pulmonary function tests were done including FEV1/FVC and 
Post-bronchodilator FEV1 
Peripheral blood samples were collected from all patients within 
24hours of admission which includes total count, differential count of 
neutrophils and lymphocytes. 
Neutrophil-to-lymphocyte ratio was calculated by dividing 
absolute neutrophil count by absolute lymphocyte count  
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LABORATORY INVESTIGATIONS 
Total leucocyte count 
Differential count of neutrophils and lymphocytes, 
COLLABORATING DEPARTMENTS 
Department of General medicine 
Department of Thoracic Medicine           
Department of Pathology 
ETHICAL  CLEARANCE: Clearance obtained 
CONSENT: Individual written and informed consent. 
ANALYSIS:  STATISTICAL ANALYSIS 
CONFLICT OF INTEREST : NIL 
FINANCIAL SUPPORT:  SELF 
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STATISTICAL ANALYSIS: 
The information collected regarding all the selected cases were 
recorded in a master chart. Data analysis was done with statistical 
software SPSS.16 software and Sigma Stat 3.5 version. 
Using this software, mean, standard deviation and p-value were 
calculated through one way ANOVA, Chi-square test .P- value of < 0.05 
was taken as significant. 
Pearson correlation coefficient was used to find correlation 
between 2 variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND 
RESULTS 
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OBSERVATIONS AND RESULTS 
AGE DISTRIBUTION IN COPD 
In our study including 80 cases, 
• 30.5% cases (12) between 41-50 years. 
• 31.5% cases (20) between 51-60 years. 
• 17.5% cases (33) between 61-70 years. 
• 16% cases (11) between 71-80 years. 
• 4.5% cases (4) between >80 years. 
 
Age No. of cases Percentage 
41 - 50 12 15 
51 - 60 20 25 
61 - 70 33 41.2 
71 - 80 11 13.8 
> 80 4 5 
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Series10
5
10
15
20
25
30
35
41 to 50 51 to 60 61 to 70 71 to 80 more than
80
12
20
33
11
4
Distribution of age among study groups
41 to 50
51 to 60
61 to 70
71 to 80
more than 80
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SEX DISTRIBUTION 
Sex No. of cases Percentage 
Male 68 85 
Female 12 15 
 
COPD is more common in males.Our study also reveals the same. The 
results of our study are as follows: 
• Males involved are 68 (85%); 
• Females involved are 12(15%). 
There is increased incidence of COPD in smokers. It is well 
documented in many studies and theories. Our study also clearly proves 
the fact of increased incidence in smokers. 
In our study, all the males were smokers and all the females were 
nonsmokers. 
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68
12
Distribution of sex among study group
gender
Male
Female
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68
12
Distribution of smoking status among study 
group
Smokers
non smokers
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SMOKING AND COPD 
In our study 68 cases (85%) out of 80 cases were smokers. Out of 
this 
• 16.2% cases had < 20 pack years. 
• 32.4% cases had 20-29 pack years. 
• 25% cases had 30-39 pack years. 
• 17.6% cases had 40-49 pack years. 
• 8.8% cases had  >50 pack years 
 
 Cases Percentage 
Smokers 68 85 
Non smokers 12 15 
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Smokers 
(Pack years) 
No. of 
cases Percentage 
< 20 11 16.2 
20 - 29 22 32.4 
30 - 39 17 25 
40-49 12 17.6 
>50 6 8.8 
 
 
 
Series10
5
10
15
20
25
< 20 20 - 29 30 - 39 40-49 >50
11
22
17
12
6
Distribution of Pack - years
< 20
20 - 29
30 - 39
40-49
>50
60 
 
BMI and COPD 
 
In our study, 
BMI No. of cases Percentage 
<18 18 22.5 
18-18.9 19 23.8 
19-19.9 21 26.2 
20-20.9 10 12.5 
21-21.9 8 10 
>22 4 5 
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0
5
10
15
20
25
less than
18
18 to 18.9 19 to 19.9 20 to 20.9 21 to 21.9 more than
22
18
19
21
10
8
4
Distribution of BMI among study group
less than 18
18 to 18.9
19 to 19.9
20 to 20.9
21 to 21.9
more than 22
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Relation between BMI and NLR 
The relation between mean BMI and NLR as also assessed in our study. 
 
NLR groups Mean BMI 
0 to 2.5 20.62 
2.6 to 5 19.21 
5.1 to 7.5 18.43 
7.6 to 10 17.8 
  
As NLR increases, mean BMI decreases. 
NLR is associated with disease severity. 
Hence, it can be inferred that lower BMI is associated with severe disease 
and poor prognosis. 
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16
16.5
17
17.5
18
18.5
19
19.5
20
20.5
21
0 to 2.5 2.6 to 5 5.1 to 7.5 7.6 to 10 Total
20.62
19.21
18.43
17.8
19.11
Distribution of mean BMI among NLR 
group
0 to 2.5
2.6 to 5
5.1 to 7.5
7.6 to 10
Total
64 
 
FEV1 % and COPD 
FEV1 < 30% (very severe) – 16.2% cases (13) 
FEV1 30 – 49% (severe) – 41.2% cases (33) 
FEV1 50 – 79% (moderate) – 27.5% cases (22) 
FEV1 80% (mild) – 15% cases (12) 
 
FEV1 % No.of cases Percentage 
<30 13 16.2 
30 – 49 33 41.2 
50 -79 22 27.5 
>80 12 15 
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0
5
10
15
20
25
30
35
less than 30 % 30% to 49% 50% to 79% more than 80%
13
33
22
12
Distribution of FEV1% predicted  among 
study group
less than 30 %
30% to 49%
50% to 79%
more than 80%
66 
 
Relation between FEV1% and NLR 
NLR FEV1%(mean) 
0 to 2.5 73 
2.6 to 5.0 51.9 
5.1 to 7.5 38.4 
7.6 to 10 27 
 
Shows significant p-value (0.001) using ANOVA test. 
That is, FEV1% decreases, NLR increases 
Ie. MORE severe the airflow obstruction (as evidenced by decreasing  
FEV1), Higher the NLR. 
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0
10
20
30
40
50
60
70
80
0 to 2.5 2.6 to 5 5.1 to 7.5 7.6 to 10 Total
73
51.929
38.4
27
49.46
Distribution of mean FEV1% among NLR 
group
0 to 2.5
2.6 to 5
5.1 to 7.5
7.6 to 10
Total
68 
 
Modified medical  research council scale(mMRC) and COPD 
In our study, 
2.5% cases had mMRC grade 0 
10% had mMRC grade 1 
37.5% had mMRC grade 2 
26.2% had mMRC grade 3 
23.8% had mMRC grade 4 
 
mMRC scale No.of cases Percentage 
0 2 2.5 
1 8 10 
2 30 37.5 
3 21 26.2 
4 19 23.8 
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0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
120.00%
0 1 2 3 4
4.00%
16.00%
38.00%
26.00%
16.00%
0.00%
0.00%
36.70%
26.70%
36.70%
2.50%
10.00%
37.50%
26.20% 23.80%
Distribution of mMRC Grade  among study groups
TOtal
Exacerbated COPD
stable COPD
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Correlation between NLR and mMRC scale 
Correlation between NL ratio grp and 
mMRC grade 
R value  
Spearman's 
rho 
NL_ratio_  
grp and 
mMRC 
grade 
Correlation 
Coefficient 
0.825** 
Positively 
correlated
p value .004  
 
The correlation coefficient between NLR and mMRC scale is 0.825. 
Hence, there is a positive correlation between NLR and mMRC scale. 
So, as the mMRC grade increases, NLR also increases. 
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6-MINUTE WALK DISTANCE AND STABLE COPD 
 6-minute walk test was performed among the 
stable COPD group. The results were as follows: 
 
6 - minute walk 
distance (metre) No.of cases Percentage 
>350 20 40 
350-349 18 36 
150-249 8 16 
<149 4 8 
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RELATION BETWEEN NLR AND 6-MINUTE WALK DISTANCE 
NLR 6-minute walk distance 
0 to 2.5 413.3 
2.6 to 5 317.6 
5.1 to 7.5 254 
7.6 to 10 133.3 
  
Shows significant p value (0.001) by ANOVA test 
AS NLR increases, the mean 6-minute walking distance decreases. 
NLR is inversely correlated with 6-minute walk distance. 
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0
50
100
150
200
250
300
350
400
450
0 to 2.5 2.6 to 5 5.1 to 7.5 7.6 to 10 Total
413.3
317.6
254
133.3
316.2
Distribution of mean 6 - minute walk 
distance among NLR group
0 to 2.5
2.6 to 5
5.1 to 7.5
7.6 to 10
Total
74 
 
BODE SCORE 
The BODE SCORE was calculated for the stable COPD group. 
The results are as follows: 
BODE SCORE No.Of Cases 
0 4 
1 4 
2 6 
3 7 
4 3 
5 4 
6 9 
7 7 
8 2 
9 0 
10 4 
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4
4
6
7
34
9
7
2 4
Distribution of BODE score  among 
Stable COPD group
0
1
2
3
4
5
6
7
8
10
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NEUTROPHIL - LYMPHOCYTE RATIO (NLR) 
  NL_ratio_grp 
P value
  0 to 2.5 2.6 to 5 5.1 to 7.5 7.6 to 10 
Stable 
COPD 
frequency 
(n) 
15 17 15 3 
0.01 
% within 30.0% 34.0% 30.0% 6.0% 
Exacerbated 
COPD 
frequency 
(n) 
2 10 15 3 
% within 6.7% 33.3% 50.0% 10.0% 
Total 
frequency 
(n) 
17 27 30 6 
 
% within 21.2% 33.8% 37.5% 7.5% 
 
In our study, 
21.2% had NLR between 0 to 2.5 
33.8% had NLR between 2.6 to 5 
37.5% had NLR between 5.1 to 7.5 
7.5 % had NLR between 7.6 to 10 
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Comparison of NLR between stable COPD and COPD exacerbation 
group 
 
Comparison of NLR between the stable and exacerbated COPD 
was done using the unpaired t-test and was found to be statistically 
significant (p value-0.008) 
It is found that NLR is higher among the COPD Exacerbation 
group as compared to stable COPD. 
Hence, it can be inferred that NLR can be used as a marker of 
COPD exacerbation. 
 
4.226
5.523333333
0
1
2
3
4
5
6
7
Stable COPD Exacerbated COPD
NL
 ra
tio
Association of NL ratio between stable 
COPD and exacerbated COPD group
Stable COPD
Exacerbated COPD
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NLR and BODE 
 
 BODE score 
Total P value
NLR 0 to 2 3 to 5 6 to 8 9 to 10 
0 to 2.5 
Count 13 2 0 0 15 
 
 
 
 
 
 
0.0001
% within bode 92.9% 14.3% .0% .0% 30.0% 
2.6 to 5 
Count 1 11 5 0 17 
% within bode 7.1% 78.6% 27.8% .0% 34.0% 
5.1 to 
7.5 
Count 0 1 13 1 15 
% within bode .0% 7.1% 72.2% 25.0% 30.0% 
7.6 to 
10 
Count 0 0 0 3 3 
% within bode .0% .0% .0% 75.0% 6.0% 
Total 
Count 14 14 18 4 50 
% within bode 100.0% 100.0% 100.0% 100.0% 100.0% 
 
 
* Shows significant p value chi square test 
As NLR increases, BODE score increases 
There is positive correlation between BODE and NLR 
Correlation coefficient +0.916 
Hence, NLR can be used to assess the disease severity as it correlates 
with BODE score. 
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DISCUSSION 
In our study, all the cases are aged above 40 years. Maximum 
number of cases(33) fell between 61-70 years. The findings of our study 
are similar to our earlier knowledge since COPD is a disease affecting 
elderly persons. 
In our study,85% of patients were males and 15% were females. 
The higher prevalence in males is probably due to the higher prevalence 
of smoking in males. 
All the males in our study are smokers and all the females are 
nonsmokers. Cigarette smoking is a major etiological risk factor for 
COPD. In our study, it is proved beyond doubt that there is a significant 
association between smoking and COPD. 
Our study shows that a low BMI is associated with a high NLR and 
severe disease. Hallin et al[10] in 2006 reported that low BMI and weight 
change ere related to a poor prognosis in COPD. Pouw et al[11] in 2000 
reported that low BMI is a risk factor for unplanned readmission. Hence, 
our results are in accord with the previous studies that further efforts are 
needed to improve the nutritional status in patients with COPD. 
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In our study, majority of patients[41.2%] came under GOLD stage 3.As 
FEV1% decreases, NLR increases.ie.as the severity of airflow obstruction 
increases, NLR increases. Thus, NLR indirectly reflects the extent of 
airflow obstruction. A possible underlying mechanism is that activated 
neutrophils cause tissue destruction in lungs by releasing oxygen radicals 
and proteolytic enzymes which results in emphysema. Emphysematous 
changes may lead to small airway obstruction. Yasar et al[ 22] in 2015 
have detected a negative correlation between NLR and FEV1%.Our study 
has also yielded the same. 
 In our study, majority (37.5%) had a mMRC dyspnoea scale of 
2.We obtained a positive correlation (0.825) between NLR and mMRC. 
 The relation between NLR and 6-minute walk distance as also 
assessed. As NLR increases, the 6-minute walk distance reduced. Thus, 
NLR and 6-minute walk distance are inversely correlated. Ryuko et al in 
2016 has also yielded similar results. 
 The relation between NLR and BODE scores were assessed. There 
is a positive correlation between NLR and BODE score with a p-value of 
0.0001 and correlation coefficient of 0.916. 
 Celli et al [24] in 2004 constructed the BODE score to predict the 
risk of death among patients with COPD. Seung et al in 2016 has 
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demonstrated the association between NLR and BODE score as well as 
with individual components of BODE. They showed significant 
correlation between NLR and BODE score, mMRC and 6 minute walk 
distance whereas no correlation was identified between NLR and BMI or 
FEV1.But our study contradicts their study in that NLR have been 
correlated well with BODE score as well as with mMRC,6-minute walk 
distance, BMI and FEV1%. 
 Another important observation was that NLR was higher among 
the COPD exacerbation group as compared to the stable COPD group 
with a p value of 0.008.Hence, it can be inferred that NLR can be used as 
a marker of COPD exacerbation. 
 Thus, NLR can be used as a prognostic indicator and determinant 
of severity of COPD is well proved statistically in our study.  
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LIMITATIONS 
 
1. Relatively small sample size 
2. BODE score could only be assessed in the stable COPD group 
3. It is a cross-sectional study, hence control groups could not be 
involved. 
  
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
• NLR was significantly higher in COPD exacerbation compared to 
patients with stable COPD 
• NLR correlated with the disease severity as it has positive 
correlation with BODE score 
• COPD is more prevalent among smokers and male sex 
• Low BMI is a risk factor for severe disease 
•  NLR correlated with the severity of airflow obstruction 
• NLR has a positive correlation with mMRC scale 
• NLR correlated inversely with 6-minutre walk distance 
• Thus, NLR correlated inversely with BMI,FEV1 %,6-minute walk 
distance and has a positive correlation with mMRC scale. 
• So, NLR has got significant correlation with BODE score as well 
as all the individual parameters in BODE score. 
• Since NLR correlates well with the disease severity in COPD, it 
should be used as a routine predictive marker of mortality in all 
patients with COPD since it is simple, cost-effective and can be 
obtained from a routine complete blood count in comparison to 
calculating the BODE score which is cumbersome.  
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ABBREVIATIONS 
 
NLR   -  Neutrophil Lymphocyte Ratio 
FEV1  -    Forced expiratory volume 
FVC  - Forced vital capacity 
COPD -    Chronic obstructive pulmonary disease 
PFT   - Pulmonary function test 
GOLD - Global guidelines for obstructive pulmonary diseases 
 
 
  
 
 
PROFORMA 
Personal details 
Age/Sex:  Occupation:                                     OP/IP No.: 
Presenting complaints: 
Grade of dyspnea (MMRC scale) 
Past history: 
Total duration of illness 
H/o DM, HIV, PT, HT, CKD, CVD, COPD etc 
Current smoker/Ex-smoker                                  Pack-years 
Clinical examination 
General examination: 
Height-                     Weight-               BMI- 
Consciousness, Pallor, Jaundice, Cyanosis, Clubbing, Lymphadenopathy, 
Pedal edema 
Vitals: PR _______ BP_______ Temperature______ RR______ SpO2___ 
Systemic examination: 
Respiratory system-  
CVS:    Abd:   CNS: 
Pulmonary Function Tests: 
FEV1-                                                           Post-bronchodilator FEV1- 
FVC- 
FEV1/FVC-                                                        GOLD STAGE- 
 
 
Laboratory investigations 
Total Leucocyte count: 
Differential count of neutrophils 
Differential count of lymphocytes 
Neutrophil-to-Lymphocyte ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
  
 
 
STABLE COPD 
S. 
N
O 
AGE SEX BMI 
SMOKING 
STATUS 
FEV1 
% 
PREDI
CTED 
GOLD 
STAGE 
mMRC 
GRAD
E 
6 
MINUTE 
WALK 
BODE 
SCORE 
NL 
RAT
IO 
    (PACK- YEARS)    
DISTAN
CE(m)   
1 62 M 20.3 40 34 3 2 280 6 2.8 
2 69 M 18.9 20 28 4 2 300 6 3.4 
3 55 M 20.5 25 36 3 2 280 5 3.8 
4 59 M 21 30 52 2 2 300 4 2.6 
5 61 M 19.2 30 26 4 4 140 10 8.2 
6 64 F 19.6 NIL 46 3 2 300 5 4.6 
7 65 M 18.5 20 38 3 3 180 7 6.2 
8 67 M 22.1 15 52 2 2 380 2 2.1 
9 58 M 21.3 10 32 3 3 280 6 5.5 
10 57 F 20.6 NIL 82 1 1 400 1 1.8 
11 66 M 19.4 25 56 2 3 260 4 3.6 
12 63 M 19.8 25 64 2 1 380 2 1.9 
13 62 M 18.6 45 44 3 1 360 3 4.8 
14 56 F 19.5 NIL 73 2 2 400 2 2.2 
15 68 M 22 30 84 1 1 400 0 1.8 
16 63 M 21.1 15 38 3 2 370 3 2.9 
17 61 M 23 20 80 1 1 500 0 2 
18 60 M 20.1 15 86 1 2 440 2 3.4 
19 65 M 18.3 20 37 3 2 300 5 5.3 
20 68 M 18.6 25 26 4 4 120 10 7.4 
21 66 M 16.2 30 58 2 2 340 4 3.6 
22 50 M 19.4 35 36 3 3 200 7 7.4 
23 59 F 19.8 NIL 56 2 2 380 3 2.8 
24 76 M 21.5 30 42 3 3 260 6 5.2 
25 66 M 19.1 35 24 4 3 240 7 5.8 
26 54 M 19.2 25 56 2 2 420 3 2.8 
27 65 M 17.6 35 36 3 3 260 6 5.6 
28 43 F 18.2 NIL 24 4 4 140 10 8.8 
29 58 M 20.1 35 54 2 2 380 3 2.4 
30 45 M 18.4 15 34 3 2 220 7 7.1 
31 66 M 20.4 30 58 2 2 360 3 3.6 
32 59 M 19.4 35 38 3 4 280 7 6.8 
33 68 M 18.4 25 46 3 3 300 6 4.4 
34 45 M 20.5 10 80 1 1 380 1 1.8 
35 56 M 18.7 20 48 3 3 230 7 6.4 
36 74 M 20.5 40 66 2 3 190 5 4.8 
 
 
37 47 M 19.6 25 54 2 3 220 6 4.8 
38 54 F 19.7 NIL 72 2 1 440 1 1.6 
39 77 M 20.6 25 68 2 2 320 3 2.2 
40 47 M 17.8 45 34 3 4 120 10 8.6 
41 67 M 19.4 20 70 2 2 420 2 2 
42 81 M 17.2 60 22 4 4 260 8 7.1 
43 68 F 19.4 NIL 38 3 3 300 6 4.3 
44 46 M 18.6 35 76 2 2 380 2 1.9 
45 52 M 22.3 15 82 1 0 500 0 1.2 
46 57 F 19.6 NIL 48 3 3 320 6 5.9 
47 48 M 21.6 20 84 1 1 440 0 1.1 
48 65 M 17.1 30 48 3 4 340 7 6.2 
49 68 M 19.8 25 44 3 4 320 8 7.4 
50 58 M 18.4 15 80 1 0 480 1 1.4 
  
 
 
COPD EXACERBATION 
 
SL. 
NO AGE SEX BMI 
SMOKING 
STATUS 
FEV1 % 
PREDICTED
GOLD 
STAGE
mMRC 
GRADE 
NL 
RATIO
    (PACK- YEARS)     
1 72 M 16.9 40 28 4 4 4.3 
2 70 M 16.3 20 44 3 4 5.6 
3 72 M 16.4 25 32 3 2 3.1 
4 78 M 17.6 30 18 4 3 5.8 
5 65 M 18 30 36 3 4 6.4 
6 63 M 18.4 20 80 1 2 4.2 
7 64 M 20 40 60 2 2 4.1 
8 68 F 18.3 NIL 66 2 2 3.5 
9 54 M 19.6 48 38 3 4 6.2 
10 60 M 18.2 50 64 2 3 5.9 
11 68 M 17.4 45 46 3 2 6.1 
12 79 M 17.2 55 40 3 4 7.2 
13 83 M 16.8 60 26 4 3 8.6 
14 50 M 16.9 48 40 3 3 7.3 
15 54 F 18 NIL 24 4 4 8.1 
16 72 M 19.6 40 56 2 2 6.7 
17 74 M 19.6 50 64 2 3 5.6 
18 70 M 21 15 82 1 2 4.3 
19 68 M 18 60 34 3 4 6.8 
20 68 M 17.4 20 86 1 2 3.9 
21 64 M 17.2 25 26 4 4 7.4 
22 44 F 18.9 NIL 36 3 3 2.8 
23 52 M 19.2 25 42 3 2 4.6 
24 82 M 21.4 15 58 2 2 1.9 
25 76 M 17.5 45 22 4 4 7.2 
26 48 F 19.4 NIL 38 3 3 4.4 
27 76 M 17.1 35 36 3 4 6.9 
28 58 M 18.4 45 35 3 3 6.4 
29 49 M 21.1 18 82 1 2 1.8 
30 85 M 16.8 30 28 4 4 8.6 
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